Cargando…

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction

The wearable cardioverter–defibrillator (WCD) is used in patients with newly diagnosed heart failure and reduced ejection fraction (HFrEF). In addition to arrhythmic events, the WCD provides near-continuous telemetric heart failure monitoring. The purpose of this study was to evaluate the clinical r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hillmann, Henrike Aenne Katrin, Hohmann, Stephan, Mueller-Leisse, Johanna, Zormpas, Christos, Eiringhaus, Jörg, Bauersachs, Johann, Veltmann, Christian, Duncker, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659567/ https://www.ncbi.nlm.nih.gov/pubmed/34883802 http://dx.doi.org/10.3390/s21237798

Ejemplares similares

Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
por: Mueller‐Leisse, Johanna, et al.
Publicado: (2021)

Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology—A PROLONG-II Substudy
por: Mueller-Leisse, Johanna, et al.
Publicado: (2022)

Eligibility for subcutaneous implantable cardioverter‐defibrillator in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

Changes in eligibility for a subcutaneous cardioverter-defibrillator after implantation of a left ventricular assist device–A prospective analysis
por: Zormpas, Christos, et al.
Publicado: (2023)

Premature end of service of implantable cardioverter-defibrillator by magnetic interference with left-ventricular assist device
por: Eiringhaus, Jörg, et al.
Publicado: (2021)

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study
por: Duncker, David, et al.
Publicado: (2017)

Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device
por: Zormpas, Christos, et al.
Publicado: (2020)

Depressive Symptoms and Quality of Life in Patients With Heart Failure and an Implantable Cardioverter-Defibrillator
por: Zormpas, Christos, et al.
Publicado: (2022)

Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure
por: Duncker, David, et al.
Publicado: (2018)

Author reply: S‐ICD eligibilities in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

Cardiac Rhythm Monitoring Using Wearables for Clinical Guidance before and after Catheter Ablation
por: Hillmann, Henrike Aenne Katrin, et al.
Publicado: (2022)

Similarly high success and low complication rates of catheter ablation for idiopathic premature ventricular contractions from the left and right ventricular outflow tract
por: Mueller-Leisse, J, et al.
Publicado: (2023)

Prediction of ablation success of idiopathic premature ventricular contractions with an inferior axis using the twelve-lead electrocardiogram
por: Mueller-Leisse, J, et al.
Publicado: (2023)

Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
por: Iliodromitis, Konstantinos, et al.
Publicado: (2023)

Usage of the wearable cardioverter-defibrillator during pregnancy
por: Olic, J.-Jacqueline, et al.
Publicado: (2022)

Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report
por: Wang, Dong, et al.
Publicado: (2023)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Telemonitoring Potential of Wearable Cardioverter-Defibrillators during the Follow-Up of Patients with Heart Failure
por: Blockhaus, Christian, et al.
Publicado: (2022)

A Tragic Case of Wearable Cardioverter-Defibrillator Failure
por: Vinas, Ariel, et al.
Publicado: (2021)

Current and future use of neuromodulation in heart failure( )
por: Duncker, David, et al.
Publicado: (2022)

Publisher Correction to: Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
Publicado: (2020)

Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting
por: Röger, Susanne, et al.
Publicado: (2018)

Wearable Cardioverter-Defibrillator Used as a Telemonitoring System in a Real-Life Heart Failure Unit Setting
por: Blockhaus, Christian, et al.
Publicado: (2021)

Assessment of heart failure parameters by telemonitoring patients with an implantable cardioverter defibrillator
por: Fily, M, et al.
Publicado: (2022)

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
por: Schäfer, Andreas, et al.
Publicado: (2021)

Deactivation of implantable cardioverter defibrillator in Japanese patients with end‐stage heart failure
por: Nakazawa, Mayui, et al.
Publicado: (2020)

Acute echocardiographic and electrocardiographic effects of triggered left ventricular pacing
por: Pfeffer, Tobias Jonathan, et al.
Publicado: (2022)

Role of deep learning methods in screening for subcutaneous implantable cardioverter defibrillator in heart failure
por: ElRefai, Mohamed, et al.
Publicado: (2022)

Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry
por: Veltmann, Christian, et al.
Publicado: (2020)

Performance of a multisensory implantable cardioverter-defibrillator algorithm for remote heart failure management: the RE-HEART registry
por: De Juan Baguda, J, et al.
Publicado: (2021)

Correction to: Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry
por: Veltmann, Christian, et al.
Publicado: (2020)

Use of Implantable Cardioverter Defibrillators in Heart Failure Patients and Risk of Mortality: A Meta-Analysis
por: Zhang, Yucong, et al.
Publicado: (2015)

Remote Monitoring of Heart Failure in Patients with Implantable Cardioverter-Defibrillators: Current Status and Future Needs
por: Theuns, Dominic A. M. J., et al.
Publicado: (2021)

Mortality among ischemic and nonischemic heart failure patients with a primary implantable cardioverter‐defibrillator
por: Yang, Pil‐Sung, et al.
Publicado: (2021)

Diagnosis of atrial fibrillation in heart failure patients with implantable cardioverter defibrillator or cardiac resynchronisation therapy
por: Dominik, Barbara, et al.
Publicado: (2021)

Animal models of heart failure with preserved ejection fraction
por: Conceição, G., et al.
Publicado: (2016)

Heart failure with recovered ejection fraction and the utility of defibrillator therapy: a review
por: Devgun, Jasneet K., et al.
Publicado: (2021)

Wearable defibrillator use in heart failure (WIF): results of a prospective registry
por: Kao, Andrew C, et al.
Publicado: (2012)

First experience with the wearable cardioverter defibrillator in the Netherlands
por: Knops, R. E., et al.
Publicado: (2011)

Wearable cardioverter defibrillator: Bridge or alternative to implantation?
por: Barraud, Jeremie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_drlrtam97uqdug29hls67arrqd